Loading...
•
Jun 30, 2021
Sight Sciences Q2 2021 Earnings Report
Reported strong second-quarter growth driven by Surgical Glaucoma and Dry Eye segments.
Key Takeaways
Sight Sciences reported a significant increase in revenue for the second quarter of 2021, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company's gross margin also saw substantial improvement. They completed an IPO raising $253 million.
Total revenue increased by 258% compared to the prior year period, reaching $12.5 million.
Surgical Glaucoma sales increased by 263% compared to the prior year period, totaling $12.0 million.
Dry Eye sales increased by 169% compared to the prior year period, reaching $0.5 million.
Gross margin expanded to 82% compared to 40% in the prior year period.
Sight Sciences
Sight Sciences
Sight Sciences Revenue by Segment
Revenue by Segment
Surgical Glaucoma Revenue
CapyFin.comDry Eye Revenue
CapyFin.com Forward Guidance
Sight Sciences projects revenue for the full year 2021 to range from $46 million to $48 million, which represents 66% to 74% growth compared to the prior year period.
Revenue & Expenses
Visualization of income flow from segment revenue to net income